Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

June 2018

Cryotherapy for Prostate Cancer Requires Prior Authorization

For dates of service beginning June 1, 2018, Harvard Pilgrim will cover cryotherapy for the treatment of prostate cancer with prior authorization for commercial members.

Cryotherapy involves freezing tumor cells in either the entire prostate gland or to localized areas where cancer is present to destroy the cells. Harvard Pilgrim considers cryotherapy medically necessary for initial treatment when documentation confirms the member has localized prostate cancer, stages T1-T3.

Salvage cryotherapy of the prostate for recurrent cancer is considered medically necessary for individuals with localized disease when documentation confirms all the following:

  • Member has failed a trial of radiation therapy as their primary treatment; AND
  • Member meets one of the following conditions:
    • Stage T2B or below, OR
      Gleason score <9, OR
    • Prostate-specific antigen (PSA) <8 ng/mL

For more information, refer to Harvard Pilgrim’s updated Cryotherapy for Prostate Cancer Medical Review Criteria. To request prior authorization, please complete the Cryotherapy for Prostate Cancer Prior Authorization Request Form and fax it to 800-232-0816.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


New Program Rewards Medicare Advantage Patients for Healthy Behaviors

GIC Product Updates Effective July 1

Introducing New Hampshire POS Open Access Plans

Harvard Pilgrim Grant Announcements


Coverage of Higher Dosage of Lupron Depot for Breast Cancer

Benign Prostatic Hypertrophy Medical Policy Updates

Cryotherapy for Prostate Cancer Requires Prior Authorization

Coverage of Fecal Calprotectin Testing

Lutathera Covered with Prior Authorization

Updates to TMJ Prior Authorization Policy

Prior Authorization No Longer Required for Cologuard Test

Follow-up WebEx on Reducing Avoidable Hospital Admissions


Negative Balance and Refund Process Enhancements

Enhanced Processes and Communication with Providers

Keep Panel Status and Demographic Information Up to Date

Early Intervention Provider Fee Schedule Update

2018 Home Care Seasonal Flu Vaccine Fee Schedule

Documenting Deep Vein Thrombus and Pulmonary Embolism


Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator